Innov-Health

Innov-Health is a healthcare-only fund operating out of Paris with an explicit focus on commercializing biomedical and digital innovations emerging from French research clusters. That research-cluster orientation is the defining feature: rather than chasing cross-border digital health momentum, the firm sits close to academic medical centers and engineering schools and tries to convert that pipeline into investable companies.

The thesis spans digital health and AI/ML in healthcare, with a bias toward companies whose technical core has roots in French biomedical engineering, clinical research, or applied machine learning. In practice that means founders are often coming from a hospital-affiliated lab, a CHU project, or a translational research environment, with the commercial work still ahead of them. The firm is comfortable with that profile and structures its support accordingly. Specific portfolio companies are not enumerated in the source material, so founders evaluating fit should ask directly about recent deployments and the cadence of clinical-to-commercial transitions in the portfolio.

Innov-Health invests at Seed and Series A with checks of one to five million dollars. The geographic focus is France, with the firm’s value most pronounced for companies anchored in French clinical and academic networks. For founders whose first customers are likely to be French hospitals or whose intellectual property originated in French research institutions, the firm’s local depth materially shortens the path from demonstration to first paying contract.

The team is composed of partners with backgrounds in healthcare investing, biomedical engineering, and clinical research. Specific partner names are not provided in the source material; founders should expect a partner-led process with sector-specialist diligence rather than a generalist software workflow.

The practical case for Innov-Health is straightforward. If a company’s technical foundation comes out of a French research cluster and its early commercial path runs through French clinical sites, the firm will know more about the institutions, reimbursement environment, and clinical champions involved than most generalist funds will ever learn. The case against is equally clear: founders building US-first or non-French commercial strategies will get less differentiated value, and the check size is not large enough to anchor capital-intensive medical device or biotech programs without significant syndicate help. Founders should come with concrete clinical evidence plans, regulatory pathway thinking, and a credible early reference site, because Innov-Health’s questions tend to start there and only later move to revenue model and growth.